Clinical OMICS

MAY-JUN 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 31 of 51

Data & Informatics 30 Clinical OMICs May/June 2018 G enomenon has announced it will partner with Veritas Genetics to develop a next-generation literature prior- itization engine the companies said will further scale the global adoption of whole-genome sequencing by reducing the time and cost of variant interpretation. The engine will incorporate proprietary genomic lan- guage processing (GLP), machine learning (ML), and arti- ficial intelligence (AI) tools—while following the American College of Medical Genetics (ACMG) and Association for Medical Pathology (AMP) variant classification frame- works, Genomenon said. "As opposed to creating targeted panels for a specific disease, the interpretation challenge greatly increases when you're looking across the entire genome without a diagno- sis," Genomenon CEO Mike Klein said. "The challenge gets even more daunting when you think about how to scale to meet the increasing demand, from hundreds of whole genomes per month to hundreds of thousands of whole genomes in the next three years. "The ability to scale the clinical interpretation of whole genome sequencing by several orders of magnitude is what prompted us to partner with Veritas," Klein added. "Ver- itas is on the leading edge of sequencing whole genomes directly for individuals." Veritas offers consumers whole-genome sequencing and interpretation services under the myGenome brand. The services are designed to yield insights on inherited disease risks, carrier status, drug sensitivities, traits, and ancestry for $999. They were the first such services to be offered for under $1,000 when launched in 2016, according to the company. Veritas says myGenome delivers for customers clinically relevant findings on more than 1,200 conditions—including some cancers, cardiovascular diseases, immune disorders, endocrine/metabolic disorders, neurological disorders, organ health or multisystem disorders, and reproductive/ carrier screening. Also included are findings on the 59 med- ically actionable genes recommended by ACMG for return in clinical genomic sequencing. Under its collaboration with Genomenon, Veritas has agreed to integrate into its current workflow and interpre- tation tools Genomenon's Mastermind Genomic Search Engine. According to Genomenon, Mastermind is the world's first search engine to connect genomic data from patients with evidence retrieved from scientific literature. Mastermind aims to comprehensively identify all clini- cally relevant and prioritized articles and is designed to link data on DNA mutations from patients with citations from scientific publications, with the goal of understanding the Learning the Literature Genomenon, Veritas Collaborate on Next-Gen Publication Prioritization Engine By Alex Philippidis The Genomenon-Veritas Collaboration will leverage machine learning and artificial intelligence to help create a literature prioritization engine with the promise of more accurate and cost-efficient variant interpretation.

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2018